Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX

0.00

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ: EWTX) with a Outperform rating and announces Price Target of $51.